A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Exclusion Criteria

• •Malignancies related to HIV or solid organ transplant.
• •Primary malignant brain tumors.
• •Chemotherapy, radiotherapy, or immunotherapy within 28 days (or 42 days for prior nitrosoureas or mitomycin C) prior to the first dose of GSK1120212. Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity are permitted with approval of a GSK Medical Monitor if dosing of that agent is terminated at least 14 days prior to the first dose of GSK1120212.
• •Use of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever is shorter preceding the first dose of GSK1120212 - as long as a minimum of 14 days has passed between the last dose of the prior investigational anti-cancer drug and the first dose of GSK1120212.
• •Previous treatment with an mTOR inhibitor unless approved by GSK Medical Monitor.
• •Previous treatment with GSK1120212.
• •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
• •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug, DMSO, or excipients. (To date there are no known FDA approved drugs chemically related to GSK1120212).
• •Use of a prohibited medication (as defined in the protocol).
• •Current use of anticoagulants (e.g. warfarin, heparin) at therapeutic levels within seven days prior to the first dose of GSK1120212. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted provided that subject's PT and PTT meet entry criteria. Subjects required therapeutic levels of LMWH must receive approval from GSK Medical Monitor and monitored appropriately as clinically indicated.
• •Gastrointestinal disease predicted to interfere with absorption of an oral drug, systemic disease, major surgery, or social/psychological issues that in the opinion of investigators would jeopardize compliance with protocol.
• •History of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
• •Predisposing factors to RVO including uncontrolled hypertension, uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy.
• •Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR.
• •Intraocular pressure \> 21mm Hg as measured by tonography.
• •Glaucoma diagnosed within 1 month prior to study Day 1.
• •Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Subjects previously treated for these conditions that are asymptomatic and off corticosteroids for at least two weeks are permitted. Subjects are not permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs).
• •Unresolved toxicity greater than common terminology criteria for adverse events (CTCAE) grade 1 from previous anti-cancer therapy except alopecia (if applicable) unless agreed to by a GSK Medical Monitor and the Investigator.
• •History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.
• •QTc interval ≥ 480 msecs.
• •Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.
• •Pregnant or lactating female.
• •History or active hepatitis B or C.
• •History of HIV infection.
• •Subjects on chronic antifungal therapy.
• •Unwillingness or inability to follow the procedures outlined in the protocol.